Next-generation AAV vectors—do not judge a virus (only) by its cover
The DOI matches its Crossref record; 149 of the 150 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated viruses (AAV) are under intensive investigation in numerous clinical trials after they have emerged as a highly promising vector for human gene therapy. Best exemplifying their power and potential is the authorization of three gene therapy products based on wild-type AAV serotypes, comprising Glybera (AAV1), Luxturna (AAV2) and, most recently, Zolgensma (AAV9). Nonetheless, it has also become evident that the current AAV vector generation will require improvements in transduction potency, antibody evasion and cell/tissue specificity to allow the use of lower and safer vector doses. To this end, others and we devoted substantial previous research to the implementation and application of key technologies for engineering of next-generation viral capsids in a high-throughput ‘top-down’ or (semi-)rational ‘bottom-up’ approach. Here, we describe a set of recent complementary strategies to enhance features of AAV vectors that act on the level of the recombinant cargo. As examples that illustrate the innovative and synergistic concepts that have been reported lately, we highlight (i) novel synthetic enhancers/promoters that provide an unprecedented degree of AAV tissue specificity, (ii) pioneering genetic circuit designs that harness biological (microRNAs) or physical (light) triggers as regulators of AAV gene expression and (iii) new insights into the role of AAV DNA structures on vector genome stability, integrity and functionality. Combined with ongoing capsid engineering and selection efforts, these and other state-of-the-art innovations and investigations promise to accelerate the arrival of the next generation of AAV vectors and to solidify the unique role of this exciting virus in human gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent review reported a rAAV-CRISPR vector that can self-inactivate its Cas9 protein by encoding an anti-Cas9 gRNA on the same construct that harbors the Cas9 itself [148].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [148]
Citations
Cites
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Efficient selection for high-expression transfectants with a novel eukaryotic vector
Hitoshi, N., Ken-ichi, Y., & Jun-ichi, M. (1991) · Gene · doi:10.1016/0378-1119(91)90434-d · Cited by 5,134
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999) · Nature Genetics · doi:10.1038/13810 · Cited by 4,990
MicroRNA genes are transcribed by RNA polymerase II
Lee, Y., Kim, M., Han, J., Yeom, K., Lee, S., Baek, S. H., & Kim, V. N. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600385 · Cited by 4,373
Mammalian microRNAs predominantly act to decrease target mRNA levels
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010) · Nature · doi:10.1038/nature09267 · Cited by 3,886
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Towards a molecular understanding of microRNA-mediated gene silencing
Jonas, S., & Izaurralde, E. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3965 · Cited by 1,872
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Self-citationA microRNA in a Multiple-Turnover RNAi Enzyme Complex
Hutvágner, G., & Zamore, P. D. (2002) · Science · doi:10.1126/science.1073827 · Cited by 1,674
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Diversifying microRNA sequence and function
Ameres, S. L., & Zamore, P. D. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3611 · Cited by 1,175
In vivo enhancer analysis of human conserved non-coding sequences
Pennacchio, L. A., Ahituv, N., Moses, A. M., Prabhakar, S., Nobrega, M. A., Shoukry, M., Minovitsky, S., Dubchak, I., Holt, A., Lewis, K. D., et al. (2006) · Nature · doi:10.1038/nature05295 · Cited by 1,165
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061
Characterization of microRNA expression profiles in normal human tissues.
Liang, Y., Ridzon, D., Wong, L., & Chen, C. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-166 · Cited by 881
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Stein, S., Ott, M. G., Schultze-Strasser, S., Jauch, A., Burwinkel, B., Kinner, A., Schmidt, M., Krämer, A., Schwäble, J., Glimm, H., et al. (2010) · Nature Medicine · doi:10.1038/nm.2088 · Cited by 716
Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Self-citationMechanisms of miRNA-mediated post-transcriptional regulation in animal cells
Chekulaeva, M., & Filipowicz, W. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.04.009 · Cited by 685
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655
Brown, B. D., Gentner, B., Cantore, A., Colleoni, S., Amendola, M., Zingale, A., Baccarini, A., Lazzari, G., Galli, C., & Naldini, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1372 · Cited by 556
Mammalian RNA polymerase II core promoters: insights from genome-wide studies
Sandelin, A., Carninci, P., Lenhard, B., Ponjavic, J., Hayashizaki, Y., & Hume, D. A. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2026 · Cited by 527
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
Induction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466
Tet-On Systems For Doxycycline-inducible Gene Expression
T. Das, A., Tenenbaum, L., & Berkhout, B. (2016) · Current Gene Therapy · doi:10.2174/1566523216666160524144041 · Cited by 434
Treatment of a metabolic liver disease by in vivo genome base editing in adult mice
Villiger, L., Grisch-Chan, H. M., Lindsay, H., Ringnalda, F., Pogliano, C. B., Allegri, G., Fingerhut, R., Häberle, J., Matos, J., Robinson, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0209-1 · Cited by 429
GFAP promoter elements required for region‐specific and astrocyte‐specific expression
Lee, Y., Messing, A., Su, M., & Brenner, M. (2008) · Glia · doi:10.1002/glia.20622 · Cited by 424
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Gray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420
Liver-specific microRNA-122: Biogenesis and function
Jopling, C. (2012) · RNA Biology · doi:10.4161/rna.18827 · Cited by 415
Londin, E., Loher, P., Telonis, A. G., Quann, K., Clark, P., Jing, Y., Hatzimichael, E., Kirino, Y., Honda, S., Lally, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420955112 · Cited by 404
Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404
Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79213 · Cited by 403
Bengtsson, N. E., Hall, J. K., Odom, G. L., Phelps, M. P., Andrus, C. R., Hawkins, R. D., Hauschka, S. D., Chamberlain, J. R., & Chamberlain, J. S. (2017) · Nature Communications · doi:10.1038/ncomms14454 · Cited by 387
Wang, Z., Ma, H.-I., Li, J., Sun, L., Zhang, J., & Xiao, X. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302133 · Cited by 367
Brooks, A. R., Harkins, R. N., Wang, P., Qian, H. S., Liu, P., & Rubanyi, G. M. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.516 · Cited by 362
Nathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
Stable knockdown of microRNA in vivo by lentiviral vectors
Gentner, B., Schira, G., Giustacchini, A., Amendola, M., Brown, B. D., Ponzoni, M., & Naldini, L. (2009) · Nature Methods · doi:10.1038/nmeth.1277 · Cited by 304
Watakabe, A., Ohtsuka, M., Kinoshita, M., Takaji, M., Isa, K., Mizukami, H., Ozawa, K., Isa, T., & Yamamori, T. (2015) · Neuroscience Research · doi:10.1016/j.neures.2014.09.002 · Cited by 303
From guide to target: molecular insights into eukaryotic RNA-interference machinery
Ipsaro, J. J., & Joshua-Tor, L. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2931 · Cited by 281
Genome-wide characterization of mammalian promoters with distal enhancer functions
Dao, L. T. M., Galindo-Albarrán, A. O., Castro-Mondragon, J. A., Andrieu-Soler, C., Medina-Rivera, A., Souaid, C., Charbonnier, G., Griffon, A., Vanhille, L., Stephen, T., et al. (2017) · Nature Genetics · doi:10.1038/ng.3884 · Cited by 281
CRISPR/Cas9‐mediated genome engineering: An adeno‐associated viral (AAV) vector toolbox
Senís, E., Fatouros, C., Große, S., Wiedtke, E., Niopek, D., Mueller, A., Börner, K., & Grimm, D. (2014) · Biotechnology Journal · doi:10.1002/biot.201400046 · Cited by 260
Self-citationA microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
Brown, B. D., Cantore, A., Annoni, A., Sergi, L. S., Lombardo, A., Della Valle, P., D'Angelo, A., & Naldini, L. (2007) · Blood · doi:10.1182/blood-2007-03-078493 · Cited by 252
AAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249
Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy
Amoasii, L., Long, C., Li, H., Mireault, A. A., Shelton, J. M., Sanchez-Ortiz, E., McAnally, J. R., Bhattacharyya, S., Schmidt, F., Grimm, D., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan8081 · Cited by 247
Self-citationA Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy
Mendell, J. R., Sahenk, Z., Malik, V., Gomez, A. M., Flanigan, K. M., Lowes, L. P., Alfano, L. N., Berry, K., Meadows, E., Lewis, S., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.200 · Cited by 246
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Le Guiner, C., Servais, L., Montus, M., Larcher, T., Fraysse, B., Moullec, S., Allais, M., François, V., Dutilleul, M., Malerba, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16105 · Cited by 246
Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences
Li, X., Eastman, E. M., Schwartz, R. J., & Draghia-Akli, R. (1999) · Nature Biotechnology · doi:10.1038/6981 · Cited by 245
VandenDriessche, T., Thorrez, L., Naldini, L., Follenzi, A., Moons, L., Berneman, Z., Collen, D., & Chuah, M. K. L. (2002) · Blood · doi:10.1182/blood.v100.3.813 · Cited by 236
The cumate gene-switch: a system for regulated expression in mammalian cells.
Mullick, A., Xu, Y. F., Warren, R. L., Koutroumanis, M., Guilbault, C., Broussau, S., Malenfant, F., Bourget, L., Lamoureux, L., Lo, R., et al. (2006) · BMC Biotechnology · doi:10.1186/1472-6750-6-43 · Cited by 231
Progresses towards safe and efficient gene therapy vectors
Chira, S., Jackson, C. S., Oprea, I., Ozturk, F., Pepper, M. S., Diaconu, I., Braicu, C., Raduly, L.-Z., Calin, G. A., & Berindan-Neagoe, I. (2015) · Oncotarget · doi:10.18632/oncotarget.5169 · Cited by 219
Weleber, R. G., Pennesi, M. E., Wilson, D. J., Kaushal, S., Erker, L. R., Jensen, L., McBride, M. T., Flotte, T. R., Humphries, M., Calcedo, R., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.003 · Cited by 218
Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy
Al‐Zaidy, S., Pickard, A. S., Kotha, K., Alfano, L. N., Lowes, L., Paul, G., Church, K., Lehman, K., Sproule, D. M., Dabbous, O., et al. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24203 · Cited by 216
Follenzi, A., Battaglia, M., Lombardo, A., Annoni, A., Roncarolo, M. G., & Naldini, L. (2004) · Blood · doi:10.1182/blood-2003-09-3217 · Cited by 212
Engineered anti-CRISPR proteins for optogenetic control of CRISPR–Cas9
Bubeck, F., Hoffmann, M. D., Harteveld, Z., Aschenbrenner, S., Bietz, A., Waldhauer, M. C., Börner, K., Fakhiri, J., Schmelas, C., Dietz, L., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0178-9 · Cited by 201
Self-citationKlein, R. L., Dayton, R. D., Leidenheimer, N. J., Jansen, K., Golde, T. E., & Zweig, R. M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.008 · Cited by 200
Tornabene, P., Trapani, I., Minopoli, R., Centrulo, M., Lupo, M., de Simone, S., Tiberi, P., Dell’Aquila, F., Marrocco, E., Iodice, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4523 · Cited by 192
Lentivirus-mediated antagomir expression for specific inhibition of miRNA function
Scherr, M., Venturini, L., Battmer, K., Schaller-Schoenitz, M., Schaefer, D., Dallmann, I., Ganser, A., & Eder, M. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm971 · Cited by 190
Xie, J., Xie, Q., Zhang, H., Ameres, S. L., Hung, J.-H., Su, Q., He, R., Mu, X., Seher Ahmed, S., Park, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.279 · Cited by 166
Construction and analysis of compact muscle-specific promoters for AAV vectors
Wang, B., Li, J., Fu, F. H., Chen, C., Zhu, X., Zhou, L., Jiang, X. L., & Xiao, X. (2008) · Gene Therapy · doi:10.1038/gt.2008.104 · Cited by 165
Parra, G., Bradnam, K., Rose, A. B., & Korf, I. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr043 · Cited by 164
Qiao, C., Yuan, Z., Li, J., He, B., Zheng, H., Mayer, C., Li, J., & Xiao, X. (2011) · Gene Therapy · doi:10.1038/gt.2010.157 · Cited by 163
Kornegay, J. N., Li, J., Bogan, J. R., Bogan, D. J., Chen, C., Zheng, H., Wang, B., Qiao, C., Howard, J. F., & Xiao, X. (2010) · Molecular Therapy · doi:10.1038/mt.2010.94 · Cited by 158
Engineered lentiviral vector targeting astrocytes In vivo
Colin, A., Faideau, M., Dufour, N., Auregan, G., Hassig, R., Andrieu, T., Brouillet, E., Hantraye, P., Bonvento, G., & Déglon, N. (2009) · Glia · doi:10.1002/glia.20795 · Cited by 158
MULLER, O., LEUCHS, B., PLEGER, S., GRIMM, D., FRANZ, W., KATUS, H., & KLEINSCHMIDT, J. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2005.12.017 · Cited by 157
Self-citationGeisler, A., Jungmann, A., Kurreck, J., Poller, W. C., Katus, H. A., Vetter, R., Fechner, H., & Müller, O. J. (2010) · Gene Therapy · doi:10.1038/gt.2010.141 · Cited by 157
Wu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300355 · Cited by 153
A New Promoter Allows Optogenetic Vision Restoration with Enhanced Sensitivity in Macaque Retina
Chaffiol, A., Caplette, R., Jaillard, C., Brazhnikova, E., Desrosiers, M., Dubus, E., Duhamel, L., Macé, E., Marre, O., Benoit, P., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.011 · Cited by 152
Favre, D., Blouin, V., Provost, N., Spisek, R., Porrot, F., Bohl, D., Marmé, F., Chérel, Y., Salvetti, A., Hurtrel, B., et al. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11605-11611.2002 · Cited by 150
High-throughput functional comparison of promoter and enhancer activities
Nguyen, T. A., Jones, R. D., Snavely, A. R., Pfenning, A. R., Kirchner, R., Hemberg, M., & Gray, J. M. (2016) · Genome Research · doi:10.1101/gr.204834.116 · Cited by 146
The University of North Carolina at Chapel Hill University Libraries (2015) · The University of North Carolina at Chapel Hill University Libraries · doi:10.17615/2x9m-k248 · Cited by 145
Mátrai, J., Cantore, A., Bartholomae, C. C., Annoni, A., Wang, W., Acosta-Sanchez, A., Samara-Kuko, E., De Waele, L., Ma, L., Genovese, P., et al. (2011) · Hepatology · doi:10.1002/hep.24230 · Cited by 139
A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing
Li, A., Lee, C. M., Hurley, A. E., Jarrett, K. E., De Giorgi, M., Lu, W., Balderrama, K. S., Doerfler, A. M., Deshmukh, H., Ray, A., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.009 · Cited by 128
Engineering the AAV capsid to optimize vector–host-interactions
Büning, H., Huber, A., Zhang, L. N., Meumann, N., & Hacker, U. T. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.08.002 · Cited by 127
Inactivation of the Very Strong HCMV Immediate Early Promoter by DNA CpG Methylation In Vitro
Prösch, S., Stein, J., Staak, K., Liebenthal, C., Volk, H.-D., & Krüger, D. H. (1996) · Biological Chemistry Hoppe-Seyler · doi:10.1515/bchm3.1996.377.3.195 · Cited by 123
Grimm, D., Pandey, K., Nakai, H., Storm, T. A., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.1.426-439.2006 · Cited by 118
Self-citationPacak, C. A., Sakai, Y., Thattaliyath, B. D., Mah, C. S., & Byrne, B. J. (2008) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-6-13 · Cited by 112
Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution
Grimm, D., & Büning, H. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.172 · Cited by 112
Self-citationCell-specific CRISPR–Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins
Hoffmann, M. D., Aschenbrenner, S., Grosse, S., Rapti, K., Domenger, C., Fakhiri, J., Mastel, M., Börner, K., Eils, R., Grimm, D., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz271 · Cited by 111
Self-citationCREME: a framework for identifying cis-regulatory modules in human-mouse conserved segments
Sharan, R., Ovcharenko, I., Ben-Hur, A., & Karp, R. M. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg1039 · Cited by 110
Grimm, D., & Zolotukhin, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.173 · Cited by 106
Self-citationShort DNA Hairpins Compromise Recombinant Adeno-Associated Virus Genome Homogeneity
Xie, J., Mao, Q., Tai, P. W. L., He, R., Ai, J., Su, Q., Zhu, Y., Ma, H., Li, J., Gong, S., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.028 · Cited by 102
Tai, P. W. L., Xie, J., Fong, K., Seetin, M., Heiner, C., Su, Q., Weiand, M., Wilmot, D., Zapp, M. L., & Gao, G. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.002 · Cited by 102
Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma
O’Callaghan, J., Crosbie, D. E., Cassidy, P. S., Sherwood, J. M., Flügel-Koch, C., Lütjen-Drecoll, E., Humphries, M. M., Reina-Torres, E., Wallace, D., Kiang, A.-S., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx028 · Cited by 86
Nair, N., Rincon, M. Y., Evens, H., Sarcar, S., Dastidar, S., Samara-Kuko, E., Ghandeharian, O., Man Viecelli, H., Thöny, B., De Bleser, P., et al. (2014) · Blood · doi:10.1182/blood-2013-10-534032 · Cited by 84
Delivering Transgenic DNA Exceeding the Carrying Capacity of AAV Vectors
Hirsch, M. L., Wolf, S. J., & Samulski, R. J. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-3271-9_2 · Cited by 84
Lecomte, E., Tournaire, B., Cogné, B., Dupont, J.-B., Lindenbaum, P., Martin-Fontaine, M., Broucque, F., Robin, C., Hebben, M., Merten, O.-W., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.32 · Cited by 83
Adeno-associated virus (AAV) vectors: Rational design strategies for capsid engineering
Lee, E. J., Guenther, C. M., & Suh, J. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.09.004 · Cited by 83
Chuah, M. K., Petrus, I., De Bleser, P., Le Guiner, C., Gernoux, G., Adjali, O., Nair, N., Willems, J., Evens, H., Rincon, M. Y., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.114 · Cited by 80
Kumar, N., Stanford, W., de Solis, C., Aradhana, Abraham, N. D., Dao, T.-M. J., Thaseen, S., Sairavi, A., Gonzalez, C. U., & Ploski, J. E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00413 · Cited by 79
Lange, A. M., Altynova, E. S., Nguyen, G. N., & Sabatino, D. E. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.64 · Cited by 78
Chenuaud, P., Larcher, T., Rabinowitz, J. E., Provost, N., Joussemet, B., Bujard, H., Samulski, R. J. S., Moullier, P., & Favre, D. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.015 · Cited by 75
Colella, P., Sellier, P., Costa Verdera, H., Puzzo, F., van Wittenberghe, L., Guerchet, N., Daniele, N., Gjata, B., Marmier, S., Charles, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.002 · Cited by 74
Design of AAV Vectors for Delivery of Large or Multiple Transgenes
Patel, A., Zhao, J., Duan, D., & Lai, Y. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_2 · Cited by 72
Majowicz, A., Maczuga, P., Kwikkers, K. L., van der Marel, S., van Logtenstein, R., Petry, H., van Deventer, S. J., Konstantinova, P., & Ferreira, V. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2712 · Cited by 71
Wooddell, C. I., Reppen, T., Wolff, J. A., & Herweijer, H. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1179 · Cited by 69
Augmentation of AAV-mediated cardiac gene transfer after systemic administration in adult rats
Müller, O. J., Schinkel, S., Kleinschmidt, J. A., Katus, H. A., & Bekeredjian, R. (2008) · Gene Therapy · doi:10.1038/gt.2008.111 · Cited by 68
de Solis, C. A., Ho, A., Holehonnur, R., & Ploski, J. E. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00070 · Cited by 66
Akbarpour, M., Goudy, K. S., Cantore, A., Russo, F., Sanvito, F., Naldini, L., Annoni, A., & Roncarolo, M. G. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3032 · Cited by 65
AAV vector-mediated in vivo reprogramming into pluripotency
Senís, E., Mosteiro, L., Wilkening, S., Wiedtke, E., Nowrouzi, A., Afzal, S., Fronza, R., Landerer, H., Abad, M., Niopek, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05059-x · Cited by 64
Self-citationPrecise tuning of gene expression levels in mammalian cells
Michaels, Y. S., Barnkob, M. B., Barbosa, H., Baeumler, T. A., Thompson, M. K., Andre, V., Colin-York, H., Fritzsche, M., Gileadi, U., Sheppard, H. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08777-y · Cited by 64
Boisgerault, F., Gross, D.-A., Ferrand, M., Poupiot, J., Darocha, S., Richard, I., & Galy, A. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.208 · Cited by 63
Next-generation muscle-directed gene therapy by in silico vector design
Sarcar, S., Tulalamba, W., Rincón, M. Y., Tipanee, J., Pham, H. Q., Evens, H., Boon, D., Samara-Kuko, E., Keyaerts, M., Loperfido, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08283-7 · Cited by 61
Native Molecular State of Adeno-Associated Viral Vectors Revealed by Single-Molecule Sequencing
Kapranov, P., Chen, L., Dederich, D., Dong, B., He, J., Steinmann, K. E., Moore, A. R., Thompson, J. F., Milos, P. M., & Xiao, W. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.160 · Cited by 60
Vigna, E., Amendola, M., Benedicenti, F., Simmons, A. D., Follenzi, A., & Naldini, L. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.11.017 · Cited by 60
Amendola, M., Giustacchini, A., Gentner, B., & Naldini, L. (2013) · Molecular Therapy · doi:10.1038/mt.2013.12 · Cited by 60
Patrício, M. I., Barnard, A. R., Orlans, H. O., McClements, M. E., & MacLaren, R. E. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.006 · Cited by 59
Sohn, J., Takahashi, M., Okamoto, S., Ishida, Y., Furuta, T., & Hioki, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169611 · Cited by 58
Benabdellah, K., Cobo, M., Muñoz, P., Toscano, M. G., & Martín, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023734 · Cited by 55
Next-generation AAV vectors for clinical use: an ever-accelerating race
Weinmann, J., & Grimm, D. (2017) · Virus Genes · doi:10.1007/s11262-017-1502-7 · Cited by 55
Self-citationRegulatory motif finding by logic regression
Keleş, S., van der Laan, M. J., & Vulpe, C. D. (2004) · Bioinformatics · doi:10.1093/bioinformatics/bth333 · Cited by 55
Armbruster, N., Lattanzi, A., Jeavons, M., Van Wittenberghe, L., Gjata, B., Marais, T., Martin, S., Vignaud, A., Voit, T., Mavilio, F., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.60 · Cited by 54
Xiao, Y., Muhuri, M., Li, S., Qin, W., Xu, G., Luo, L., Li, J., Letizia, A. J., Wang, S. K., Chan, Y. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99052 · Cited by 53
Rincón, M. Y., Sarcar, S., Danso‐Abeam, D., Keyaerts, M., Mátrai, J., Samara-Kuko, E., Acosta‐Sanchez, A., Athanasopoulos, T., Dickson, G., Lahoutte, T., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.178 · Cited by 50
Le Guiner, C., Stieger, K., Toromanoff, A., Guilbaud, M., Mendes-Madeira, A., Devaux, M., Guigand, L., Cherel, Y., Moullier, P., Rolling, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102538 · Cited by 50
CRISPR/Cas9- loxP -Mediated Gene Editing as a Novel Site-Specific Genetic Manipulation Tool
Yang, F., Liu, C., Chen, D., Tu, M., Xie, H., Sun, H., Ge, X., Tang, L., Li, J., Zheng, J., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.018 · Cited by 50
Kuroda, H., Kutner, R. H., Bazan, N. G., & Reiser, J. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1249 · Cited by 47
Guilbaud, M., Devaux, M., Couzinié, C., Le Duff, J., Toromanoff, A., Vandamme, C., Jaulin, N., Gernoux, G., Larcher, T., Moullier, P., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.234 · Cited by 45
Huang, W., Liu, X., Queen, N. J., & Cao, L. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.06.002 · Cited by 41
Design and Testing of Regulatory Cassettes for Optimal Activity in Skeletal and Cardiac Muscles
Himeda, C. L., Chen, X., & Hauschka, S. D. (2011) · Methods in Molecular Biology · doi:10.1007/978-1-61737-982-6_1 · Cited by 40
Greig, J. A., Wang, Q., Reicherter, A. L., Chen, S.-J., Hanlon, A. L., Tipper, C. H., Clark, K. R., Wadsworth, S., Wang, L., & Wilson, J. M. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.128 · Cited by 40
Geisler, A., Schön, C., Größl, T., Pinkert, S., Stein, E. A., Kurreck, J., Vetter, R., & Fechner, H. (2013) · Molecular Therapy · doi:10.1038/mt.2012.276 · Cited by 36
RILES, a novel method for temporal analysis of the in vivo regulation of miRNA expression
Ezzine, S., Vassaux, G., Pitard, B., Barteau, B., Malinge, J., Midoux, P., Pichon, C., & Baril, P. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt797 · Cited by 36
Split Cas9, Not Hairs − Advancing the Therapeutic Index of CRISPR Technology
Schmelas, C., & Grimm, D. (2018) · Biotechnology Journal · doi:10.1002/biot.201700432 · Cited by 35
Self-citationTranscriptomics-Guided Design of Synthetic Promoters for a Mammalian System
Cheng, J. K., & Alper, H. S. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.6b00075 · Cited by 35
Hu, C., Kasten, J., Park, H., Bhargava, R., Tai, D. S., Grody, W. W., Nguyen, Q. G., Hauschka, S. D., Cederbaum, S. D., & Lipshutz, G. S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.99 · Cited by 33
Adeno-associated virus inverted terminal repeats stimulate gene editing
Hirsch, M. L. (2015) · Gene Therapy · doi:10.1038/gt.2014.109 · Cited by 32
Chen, S.-J., Johnston, J., Sandhu, A., Bish, L. T., Hovhannisyan, R., Jno-Charles, O., Sweeney, H. L., & Wilson, J. M. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.129 · Cited by 32
Wang, L., Wang, Z., Zhang, F., Zhu, R., Bi, J., Wu, J., Zhang, H., Liu, H., Kong, W., Yu, B., et al. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.14152 · Cited by 30
Kia, A., Yata, T., Hajji, N., & Hajitou, A. (2013) · Viruses · doi:10.3390/v5102561 · Cited by 29
Gray, A. L., O’Leary, C., Liao, A., Agúndez, L., Youshani, A. S., Gleitz, H. F. E., Parker, H., Taylor, J., Danos, O., Hocquemiller, M., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.189 · Cited by 29
Veron, P., Boutin, S., Martin, S., Chaperot, L., Plumas, J., Davoust, J. M., & Masurier, C. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-10 · Cited by 28
Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors
Ling, C., Yin, Z., Li, J., Zhang, D., Aslanidi, G., & Srivastava, A. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.29 · Cited by 26
Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors
Merlin, S., & Follenzi, A. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.013 · Cited by 25
Redchuk, T. A., Karasev, M. M., Omelina, E. S., & Verkhusha, V. V. (2018) · ChemBioChem · doi:10.1002/cbic.201700642 · Cited by 25
Gernoux, G., Guilbaud, M., Dubreil, L., Larcher, T., Babarit, C., Ledevin, M., Jaulin, N., Planel, P., Moullier, P., & Adjali, O. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.070 · Cited by 23
Markusic, D. M., de Waart, D. R., & Seppen, J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009974 · Cited by 22
Bleser, P. D., Hooghe, B., Vlieghe, D., & Roy, F. M. V. (2007) · Genome biology · doi:10.1186/gb-2007-8-5-r83 · Cited by 22
CRISPR Activation Enhances In Vitro Potency of AAV Vectors Driven by Tissue-Specific Promoters
McDougald, D. S., Duong, T. T., Palozola, K. C., Marsh, A., Papp, T. E., Mills, J. A., Zhou, S., & Bennett, J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.03.004 · Cited by 21
POCO: discovery of regulatory patterns from promoters of oppositely expressed gene sets
Kankainen, M., & Holm, L. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki467 · Cited by 21
Serrano-Mendioroz, I., Sampedro, A., Alegre, M., de Salamanca, R. E., Berraondo, P., & Fontanellas, A. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.056 · Cited by 20
Reid, C. A., Boye, S. L., Hauswirth, W. W., & Lipinski, D. M. (2017) · Gene Therapy · doi:10.1038/gt.2017.50 · Cited by 16
Dhungel, B. P., Ramlogan‐Steel, C. A., & Steel, J. C. (2018) · Scientific Reports · doi:10.1038/s41598-018-33801-4 · Cited by 15
Pichard, V., Aubert, D., Boni, S., Battaglia, S., Ivacik, D., Nguyen, T. H., Arbuthnot, P. B., & Ferry, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051952 · Cited by 15
Bockstael, O., Tenenbaum, L., Dalkara, D., Melas, C., Witte, O. D., Levivier, M., & Chtarto, A. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00092 · Cited by 10
An improved AAV vector for neurological correction of the mouse model of Mucopolysaccharidosis IIIA
Gray, A., O’Leary, C., Liao, A., et al. (2019) · UCL Discovery (University College London) · Cited by 1
Cited by
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
“These topics were discussed in depth in recent reviews (Colella et al., 2017; Domenger and Grimm, 2019; Rabinowitz et al., 2019; Verdera et al., 2020; Wang et al., 2019).”
CRISPR-Cas9 DNA Base-Editing and Prime-Editing
Kantor, A., McClements, M., & MacLaren, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176240 · Cited by 462
Role of circular RNAs in brain development and CNS diseases
Mehta, S. L., Dempsey, R. J., & Vemuganti, R. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101746 · Cited by 281
“US FDA recently approved Zolgensma, which is an adenovirus-based gene therapy to correct bi-allelic mutations in survival motor neuron 1 (SMN1) gene and LUXTURNA (voretigene neparvovec-rzyl) to deliver a normal copy of the RPE65 gene to correct a biallelic RPE65 mutation in patients with retinal dystrophy (Domenger an…”
BackgroundAAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9
Li, A., Tanner, M. R., Lee, C. M., Hurley, A. E., De Giorgi, M., Jarrett, K. E., Davis, T. H., Doerfler, A. M., Bao, G., Beeton, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.04.017 · Cited by 230
Durability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
“For example, use of a strong enhancer element upstream of a tissue-specific promoter can allow for strong transgene expression in the desired tissue.(100,154,157,158) More recently, in silico engineering of a muscle-specific promoter, Sk-CRM4/Des, within a self-complementary AAV9 vector, resulted in up to 173-fold inc…”
Background
Metadata
- Authors
- Domenger, C., & Grimm, D.
- Affiliations
- University Hospital Heidelberg (DE)
- Corresponding author
- Grimm, Dirk
- ORCID
- Grimm, Dirk
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-02
- Volume
- 28
- Issue
- R1
- Pages
- R3-R14
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2954423091
- Cited by
- 147
- References
- 150
- Citations by year
- 2026: 19 · 2025: 14 · 2024: 17 · 2023: 26 · 2022: 24 · 2021: 21 · 2020: 24 · 2019: 2
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- German Research Foundation
- German Center for Infection Research (TTU-HIV 04.815, TTU-HIV 04.803)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus vectors, gene therapy vectors, capsid engineering, tissue-specific promoters, synthetic enhancers, synthetic gene circuits, microRNA regulation, antibody escape
- MeSH terms
- Dependovirus, Animals, Enhancer Elements, Genetic, Gene Expression Regulation, Genetic Engineering, Genetic Vectors, Humans, Promoter Regions, Genetic, Transduction, Genetic, Genetic Therapy, Transgenes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.